Pharmaceutical

Ethris and Lonza to develop mRNA vaccines for respiratory conditions

Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory conditions.

Apr 8, 2025 - 06:00
Ethris and Lonza to develop mRNA vaccines for respiratory conditions
Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory conditions.
Read the original article

Tags:

Previous Article

New Study Reveals 1 in 3,000 Individuals at Risk of Punctured Lung Due to Geneti...

Next Article

Africa: The clinical impact of the US withdrawal from WHO and USAID

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: STAT+: Health care AI requires a new Hippocratic oath

Opinion: STAT+: Health care AI requires a new Hippocrat...

Dec 9, 2023

Eloxx moves ahead with plans with gene therapy for rare kidney disorder

Eloxx moves ahead with plans with gene therapy for rare...

Sep 9, 2023

STAT+: As the obesity drug market grows, digital health companies juggle patients and payers

STAT+: As the obesity drug market grows, digital health...

Aug 21, 2023